Recursion: No Longer An AI 'Pet Science Project,' But Still A 'Sell'
Recursion Pharmaceuticals (RXRX) is no longer seen as just an AI-driven 'pet science project,' but it remains a 'Sell' due to a lack of clinical or commercial progress supporting its ~$1.8 billion valuation. Its lead candidate, REC-4881, shows unremarkable efficacy in FAP compared to existing treatments like Celebrex, with unclear regulatory and market uptake potential. The oncology pipeline faces stiff competition and lacks differentiation or near-term catalysts, while partnership revenue is inconsistent and insufficient to cover ongoing losses. Despite a cash runway extending into early 2028, the company continues to report quarterly losses exceeding $100 million.
- ▪Recursion Pharmaceuticals (RXRX) maintains a ~$1.8B market valuation despite no significant clinical or commercial achievements.
- ▪REC-4881's Phase 1/2 results in FAP show modest efficacy compared to Celebrex, raising doubts about regulatory approval and physician adoption.
- ▪The oncology pipeline, including REC-617 and REC-3565, lacks differentiation amid a competitive landscape and has no imminent catalysts.
- ▪Revenue from partnerships is milestone-dependent and irregular, failing to offset Recursion's consistent quarterly losses over $100M.
- ▪The company's cash reserves are sufficient to fund operations into early 2028.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://seekingalpha.com/"},{"@type":"ListItem","position":2,"name":"Healthcare ","item":"https://seekingalpha.com/stock-ideas/healthcare"}]}{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4895089-recursion-no-longer-an-ai-pet-science-project-but-still-a-sell"},"author":{"@type":"Person","name":"Stephen Ayers","url":"https://seekingalpha.com/author/stephen-ayers"},"publisher":{"@context":"http://schema.org","@type":"Organization","address":{"@type":"PostalAddress","streetAddress":"244 5th Ave","addressLocality":"New…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
